Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Orientbio Inc. (002630:KRX), powered by AI.
Orientbio Inc. is currently trading at ₩547. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Orientbio Inc. on Alpha Lenz.
Orientbio Inc.'s P/E ratio is -4.9.
“Orientbio Inc. trades at a P/E of -4.9 (undervalued) with modest ROE of -16.8%.”
Ask for details →Orientbio Inc. operates as a biotechnology company primarily engaged in the research, development, and commercialization of advanced biotechnological products and solutions. The company's core focus is on delivering cutting-edge innovations in life sciences, targeting diverse areas such as biomedical research, diagnostic applications, and therapeutic solutions. With its extensive expertise in genetic engineering and molecular biology, Orientbio Inc. plays a significant role in the pharmaceutical and healthcare industries by facilitating the development of essential medical breakthroughs. Furthermore, the company is involved in producing and supplying high-quality biological materials and services to research institutions and biopharma companies worldwide. Through its contributions, Orientbio Inc. is pivotal in advancing medical research, improving disease understanding, and supporting the creation of novel treatments. By harnessing the potentials of biotechnology, it remains an influential entity in the ongoing efforts to address global health challenges.
“Orientbio Inc. trades at a P/E of -4.9 (undervalued) with modest ROE of -16.8%.”
Ask for details →Orientbio Inc. (ticker: 002630) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $64.9B.
The current price is ₩547 with a P/E ratio of -4.92x and P/B of 0.9x.
ROE is -16.81% and operating margin is -10.46%. Annual revenue is $29.4B.